Annexon Biosciences
A Vice President, Clinical Development-Neuroscience at Annexon Biosciences leads the strategic direction and execution of clinical development programs for neurodegenerative and neuro-immunologic diseases, ensuring regulatory compliance and scientific integrity.
Headquarters
South San Francisco, California, United States
Company Size
51-200 employees
Founded
2011
Annexon Biosciences is a biopharmaceutical company developing next‑generation complement therapies by targeting C1q, the initiating molecule of the classical complement pathway. By blocking C1q, Annexon aims to prevent downstream immune‑mediated damage in autoimmune, neurodegenerative (including Alzheimer’s and Huntington’s) and ophthalmic diseases affecting the body, brain, and eye. The company advances C1q‑targeted biologics through a pipeline of therapeutic candidates intended to provide disease‑modifying treatments for conditions driven by classical complement activation.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Annexon Biosciences.
104% above the average for this role
Annexon Biosciences stock rating reiterated by Cantor Fitzgerald
Jan 14, 2026
Senior Advisor, Clinical Research, Neuroscience
Eli Lilly and Company
Sr. Clinical Development Director, NEUROSCIENCE (REMOTE)
Ipsen
Executive Medical Director, Clinical Development, Neurodegeneration
Neurocrine Biosciences
Executive Medical Director, Global Medical Affairs, Neuroscience
Diversity Employment
Vice President, Head of Clinical Development – Allergy & Urticaria
ARS Pharmaceuticals
Vice President, Research (Neuroscience)
Regeneron Pharmaceuticals